A contactless cure: Leveraging telehealth to improve hepatitis C treatment at a safety‐net hospital

Hepatitis C virus (HCV) causes significant mortality worldwide. HCV is highly curable but access to care is limited for many patients. The Grady Liver Clinic (GLC), a primary care‐based HCV clinic, utilizes a multidisciplinary team to provide comprehensive care for a medically underserved patient po...

Full description

Saved in:
Bibliographic Details
Published inJournal of viral hepatitis Vol. 31; no. 4; pp. 176 - 180
Main Authors Frye, Krysta, Davis, Andrew, Darby, Rapheisha, McDaniel, Kathryn, Quairoli, Kristi, Liu, Zhanxu, Miller, Lesley S., Fluker, Shelly‐Ann
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.04.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Hepatitis C virus (HCV) causes significant mortality worldwide. HCV is highly curable but access to care is limited for many patients. The Grady Liver Clinic (GLC), a primary care‐based HCV clinic, utilizes a multidisciplinary team to provide comprehensive care for a medically underserved patient population in Atlanta, Georgia. The GLC added a telehealth option for HCV treatment at the start of the COVID‐19 pandemic. We describe the outcomes of utilizing telehealth in this population. We performed a retrospective chart review of patients who initiated HCV treatment from March 2019 to February 2020 (pre‐pandemic) and March 2020 to February 2021 (pandemic). Charts were ed for patient demographics and characteristics, treatment regimen, and treatment outcomes. Our primary outcome was HCV cure rate of the pre‐pandemic compared to the pandemic cohorts and within the different pandemic cohort visit types. We performed an intention‐to‐treat (ITT) analysis for all patients who took at least one dose of a direct‐acting antiviral (DAA) regardless of therapy completion, and a per‐protocol (PP) analysis of those who completed treatment and were tested for HCV cure. SVR12 rates were >95% on ITT analysis, with no significant difference between pre‐pandemic and pandemic cohorts. There was also no significant difference within the pandemic group when treatment was provided traditionally, via telehealth, or via a hybrid of these. Our findings support the use of telehealth as a tool to expand access to HCV treatment in a medically underserved patient population.
AbstractList Hepatitis C virus (HCV) causes significant mortality worldwide. HCV is highly curable but access to care is limited for many patients. The Grady Liver Clinic (GLC), a primary care-based HCV clinic, utilizes a multidisciplinary team to provide comprehensive care for a medically underserved patient population in Atlanta, Georgia. The GLC added a telehealth option for HCV treatment at the start of the COVID-19 pandemic. We describe the outcomes of utilizing telehealth in this population. We performed a retrospective chart review of patients who initiated HCV treatment from March 2019 to February 2020 (pre-pandemic) and March 2020 to February 2021 (pandemic). Charts were abstracted for patient demographics and characteristics, treatment regimen, and treatment outcomes. Our primary outcome was HCV cure rate of the pre-pandemic compared to the pandemic cohorts and within the different pandemic cohort visit types. We performed an intention-to-treat (ITT) analysis for all patients who took at least one dose of a direct-acting antiviral (DAA) regardless of therapy completion, and a per-protocol (PP) analysis of those who completed treatment and were tested for HCV cure. SVR12 rates were >95% on ITT analysis, with no significant difference between pre-pandemic and pandemic cohorts. There was also no significant difference within the pandemic group when treatment was provided traditionally, via telehealth, or via a hybrid of these. Our findings support the use of telehealth as a tool to expand access to HCV treatment in a medically underserved patient population.
Hepatitis C virus (HCV) causes significant mortality worldwide. HCV is highly curable but access to care is limited for many patients. The Grady Liver Clinic (GLC), a primary care‐based HCV clinic, utilizes a multidisciplinary team to provide comprehensive care for a medically underserved patient population in Atlanta, Georgia. The GLC added a telehealth option for HCV treatment at the start of the COVID‐19 pandemic. We describe the outcomes of utilizing telehealth in this population. We performed a retrospective chart review of patients who initiated HCV treatment from March 2019 to February 2020 (pre‐pandemic) and March 2020 to February 2021 (pandemic). Charts were ed for patient demographics and characteristics, treatment regimen, and treatment outcomes. Our primary outcome was HCV cure rate of the pre‐pandemic compared to the pandemic cohorts and within the different pandemic cohort visit types. We performed an intention‐to‐treat (ITT) analysis for all patients who took at least one dose of a direct‐acting antiviral (DAA) regardless of therapy completion, and a per‐protocol (PP) analysis of those who completed treatment and were tested for HCV cure. SVR12 rates were >95% on ITT analysis, with no significant difference between pre‐pandemic and pandemic cohorts. There was also no significant difference within the pandemic group when treatment was provided traditionally, via telehealth, or via a hybrid of these. Our findings support the use of telehealth as a tool to expand access to HCV treatment in a medically underserved patient population.
Author Darby, Rapheisha
McDaniel, Kathryn
Liu, Zhanxu
Fluker, Shelly‐Ann
Quairoli, Kristi
Miller, Lesley S.
Frye, Krysta
Davis, Andrew
Author_xml – sequence: 1
  givenname: Krysta
  surname: Frye
  fullname: Frye, Krysta
  organization: Emory University School of Medicine
– sequence: 2
  givenname: Andrew
  surname: Davis
  fullname: Davis, Andrew
  organization: Emory University School of Medicine
– sequence: 3
  givenname: Rapheisha
  surname: Darby
  fullname: Darby, Rapheisha
  organization: Grady Health System
– sequence: 4
  givenname: Kathryn
  surname: McDaniel
  fullname: McDaniel, Kathryn
  organization: Department of Pharmacy, Grady Health System
– sequence: 5
  givenname: Kristi
  surname: Quairoli
  fullname: Quairoli, Kristi
  organization: Department of Pharmacy, Grady Health System
– sequence: 6
  givenname: Zhanxu
  surname: Liu
  fullname: Liu, Zhanxu
  organization: Emory University
– sequence: 7
  givenname: Lesley S.
  surname: Miller
  fullname: Miller, Lesley S.
  organization: Emory University School of Medicine
– sequence: 8
  givenname: Shelly‐Ann
  orcidid: 0000-0002-8439-3598
  surname: Fluker
  fullname: Fluker, Shelly‐Ann
  email: shelly‐ann.fluker@emory.edu
  organization: Emory University School of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38369695$$D View this record in MEDLINE/PubMed
BookMark eNp10MtKAzEUBuAgiveFLyABN7oYO5lcJnEnRa1ScKNuh9PxjDNlLjXJVLrzEXxGn8TUVheCIZAsPn7O-ffIZtu1SMgRi89ZOIPpvDxn3DC-QXYZVzJKtOGby79MoljGYofsOTeNY8YTybbJDtdcGWXkLsFLmneth9zX6BzNe4sXdIxztPBStS_UY40lQu1L6jtaNTPbzZGWOANf-crRIfUWwTfYegrhUgcF-sXn-0eLnpadm1Ue6gOyVUDt8HD97pPH66uH4Sga39_cDi_HUc4Z5xFIjYURwBGUMKlKQSY6ViZmKFRYlCtWGGQGAXIJaLRWgBMuBGP4PCkKvk9OV7lhzNcenc-ayuVY19Bi17ssMYmWWiQiDfTkD512vW3DdEHJlIkk1Tyos5XKbeecxSKb2aoBu8hYnC27z0L32Xf3wR6vE_tJg8-_8qfsAAYr8FbVuPg_Kbt7Gq0ivwB4yZBh
Cites_doi 10.1007/s10620-013-2810-y
10.7326/M16-2575
10.1002/hep.30297
10.1002/hep.31060
10.1111/jgh.15492
10.1177/00333549231170205
10.1016/j.cgh.2020.09.011
10.1016/j.cgh.2017.10.004
10.1016/j.drugpo.2017.05.032
10.1177/1357633X16673794
10.1093/ofid/ofz128
10.1177/0033354919888228
10.1177/1357633X18795361
10.1258/jtt.2012.120612
10.1177/1357633X19885750
10.1016/j.jsat.2016.12.014
10.1016/j.drugpo.2018.06.019
10.1016/s0027-9684(15)30161-9
10.1155/2014/195097
10.1111/jvh.13017
10.5604/01.3001.0010.5277
10.17235/reed.2019.6152/2018
10.1177/1357633X18806651
ContentType Journal Article
Copyright 2024 John Wiley & Sons Ltd.
Copyright © 2024 John Wiley & Sons Ltd
Copyright_xml – notice: 2024 John Wiley & Sons Ltd.
– notice: Copyright © 2024 John Wiley & Sons Ltd
DBID NPM
AAYXX
CITATION
7U9
H94
K9.
7X8
DOI 10.1111/jvh.13913
DatabaseName PubMed
CrossRef
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Virology and AIDS Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
CrossRef
AIDS and Cancer Research Abstracts

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1365-2893
EndPage 180
ExternalDocumentID 10_1111_jvh_13913
38369695
JVH13913
Genre article
Journal Article
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
29L
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAKAS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZCM
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHEFC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DTERQ
DU5
EAD
EAP
EAS
EBC
EBD
EBS
EBX
EJD
EMB
EMK
EMOBN
EPT
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YFH
YUY
ZZTAW
~IA
~WT
NPM
AAMNL
AAYXX
ACRPL
ACYXJ
CITATION
7U9
H94
K9.
7X8
ID FETCH-LOGICAL-c3133-a58ef94a3ea649767a52806901e46111361f9e19eaac5ae9886aeb34411edbff3
IEDL.DBID DR2
ISSN 1352-0504
IngestDate Fri Dec 06 00:10:53 EST 2024
Fri Nov 29 08:18:28 EST 2024
Fri Dec 06 04:10:59 EST 2024
Sat Nov 02 12:25:45 EDT 2024
Sat Aug 24 00:50:40 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords telemedicine
urban population
vulnerable populations
chronic disease
hepatitis C
Language English
License 2024 John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3133-a58ef94a3ea649767a52806901e46111361f9e19eaac5ae9886aeb34411edbff3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-8439-3598
PMID 38369695
PQID 2957142783
PQPubID 1086372
PageCount 5
ParticipantIDs proquest_miscellaneous_2928584247
proquest_journals_2957142783
crossref_primary_10_1111_jvh_13913
pubmed_primary_38369695
wiley_primary_10_1111_jvh_13913_JVH13913
PublicationCentury 2000
PublicationDate April 2024
2024-Apr
2024-04-00
20240401
PublicationDateYYYYMMDD 2024-04-01
PublicationDate_xml – month: 04
  year: 2024
  text: April 2024
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
PublicationTitle Journal of viral hepatitis
PublicationTitleAlternate J Viral Hepat
PublicationYear 2024
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2021; 36
2013; 19
2017; 75
2021; 27
2013; 58
2019; 6
2023
2017; 47
2020
2017; 16
2020; 71
2019; 26
2021; 19
2019; 69
2020; 26
2014; 2014
2020; 135
2017; 166
2012; 104
2018; 16
2019; 111
2018; 59
2018; 24
2016; 22
e_1_2_9_11_1
e_1_2_9_10_1
e_1_2_9_13_1
e_1_2_9_12_1
e_1_2_9_15_1
e_1_2_9_14_1
e_1_2_9_17_1
e_1_2_9_16_1
e_1_2_9_19_1
e_1_2_9_18_1
e_1_2_9_20_1
e_1_2_9_22_1
e_1_2_9_21_1
e_1_2_9_24_1
e_1_2_9_23_1
e_1_2_9_8_1
e_1_2_9_7_1
e_1_2_9_6_1
e_1_2_9_5_1
e_1_2_9_4_1
e_1_2_9_3_1
e_1_2_9_2_1
e_1_2_9_9_1
e_1_2_9_26_1
e_1_2_9_25_1
e_1_2_9_28_1
e_1_2_9_27_1
e_1_2_9_29_1
References_xml – volume: 26
  start-page: 101
  issue: 1
  year: 2019
  end-page: 108
  article-title: Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine
  publication-title: J Viral Hepat
– volume: 69
  start-page: 1020
  issue: 3
  year: 2019
  end-page: 1031
  article-title: Estimating prevalence of hepatitis C virus infection in the United States, 2013–2016
  publication-title: Hepatology
– volume: 135
  start-page: 107
  issue: 1
  year: 2020
  end-page: 113
  article-title: Improved hepatitis C cure Cascade outcomes among urban baby boomers in the direct‐acting antiviral era
  publication-title: Public Health Rep
– volume: 36
  start-page: 2285
  issue: 8
  year: 2021
  end-page: 2291
  article-title: Differences in inpatient and outpatient hepatitis C virus prevalence and linkage to care rates in a safety net hospital hepatitis C screening program
  publication-title: J Gastroenterol Hepatol
– volume: 166
  start-page: 637
  issue: 9
  year: 2017
  end-page: 648
  article-title: Oral direct acting agent therapy for hepatitis C virus infection. A systematic review
  publication-title: Ann Intern Med
– volume: 22
  start-page: 459
  issue: 8
  year: 2016
  end-page: 464
  article-title: Use of telehealth to treat and manage chronic viral hepatitis in regional Queensland
  publication-title: J Telemed Telecare
– volume: 111
  start-page: 550
  issue: 7
  year: 2019
  end-page: 555
  article-title: The contribution of telemedicine to hepatitis C elimination in a correctional facility
  publication-title: Rev Esp Enferm Dig
– volume: 58
  start-page: 3620
  issue: 12
  year: 2013
  end-page: 3625
  article-title: Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation in northern California
  publication-title: Dig Di Sci
– volume: 27
  start-page: 463
  issue: 7
  year: 2021
  end-page: 468
  article-title: Comparison of hepatitis C treatment outcomes between telehepatology and specialty care clinics in the era of direct‐acting antivirals
  publication-title: J Telemed Telecare
– volume: 19
  start-page: 1139
  issue: 6
  year: 2021
  end-page: 1150.e30
  article-title: eHealth technologies for screening, diagnosis, and management of viral hepatitis: a systematic review
  publication-title: Clin Gastroenterol Hepatol
– volume: 71
  start-page: 686
  issue: 2
  year: 2020
  end-page: 721
  article-title: Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection
  publication-title: Hepatology
– volume: 16
  start-page: 157
  issue: 2
  year: 2018
  end-page: 161.e8
  article-title: Current and future applications of telemedicine to optimize the delivery of Care in Chronic Liver Disease
  publication-title: Clin Gastroenterol Hepatol
– volume: 19
  start-page: 101
  issue: 2
  year: 2013
  end-page: 106
  article-title: Successful treatment of patients with hepatitis C in rural and remote Western Australia via telehealth
  publication-title: J Telemed Telecare
– year: 2020
– year: 2023
– volume: 24
  start-page: 690
  issue: 10
  year: 2018
  end-page: 696
  article-title: Telementoring for hepatitis C treatment in correctional facilities
  publication-title: J Telemed Telecare
– volume: 2014
  year: 2014
  article-title: Translational research of telecare for the treatment of hepatitis C
  publication-title: Biomed Res Int
– year: 2023
  article-title: Large‐scale, primary care–based hepatitis C treatment in an urban, medically underserved patient population
  publication-title: Public Health Rep
– volume: 104
  start-page: 244
  issue: 5–6
  year: 2012
  end-page: 250
  article-title: Improving access to hepatitis C care for urban, underserved patients using a primary care–based hepatitis C clinic
  publication-title: J Natl Med Assoc
– volume: 75
  start-page: 49
  year: 2017
  end-page: 53
  article-title: Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program
  publication-title: J Subst Abus Treat
– volume: 6
  issue: 7
  year: 2019
  article-title: Retrospective study demonstrating high rates of sustained virologic response after treatment with direct‐acting antivirals among American Indian/Alaskan natives
  publication-title: Open Forum Infect Dis
– volume: 16
  start-page: 874
  issue: 6
  year: 2017
  end-page: 880
  article-title: Direct‐acting antiviral therapy outcomes in Canadian chronic hepatitis C telemedicine patients
  publication-title: Ann Hepatol
– volume: 47
  start-page: 209
  year: 2017
  end-page: 215
  article-title: Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting
  publication-title: Int J Drug Policy
– volume: 59
  start-page: 76
  year: 2018
  end-page: 84
  article-title: Factors associated with lost to follow‐up after hepatitis C treatment delivered by primary care teams in an inner‐city multi‐site program, Vancouver, Canada
  publication-title: Int J Drug Policy
– volume: 26
  start-page: 180
  issue: 3
  year: 2020
  end-page: 185
  article-title: Using telehealth to improve access to hepatitis C treatment in the direct‐acting antiviral therapy era
  publication-title: J Telemed Telcare
– ident: e_1_2_9_22_1
  doi: 10.1007/s10620-013-2810-y
– ident: e_1_2_9_14_1
– ident: e_1_2_9_4_1
  doi: 10.7326/M16-2575
– ident: e_1_2_9_3_1
– ident: e_1_2_9_11_1
  doi: 10.1002/hep.30297
– ident: e_1_2_9_5_1
  doi: 10.1002/hep.31060
– ident: e_1_2_9_10_1
  doi: 10.1111/jgh.15492
– ident: e_1_2_9_12_1
  doi: 10.1177/00333549231170205
– ident: e_1_2_9_6_1
  doi: 10.1016/j.cgh.2020.09.011
– ident: e_1_2_9_7_1
– ident: e_1_2_9_8_1
  doi: 10.1016/j.cgh.2017.10.004
– ident: e_1_2_9_16_1
  doi: 10.1016/j.drugpo.2017.05.032
– ident: e_1_2_9_20_1
  doi: 10.1177/1357633X16673794
– ident: e_1_2_9_21_1
  doi: 10.1093/ofid/ofz128
– ident: e_1_2_9_9_1
  doi: 10.1177/0033354919888228
– ident: e_1_2_9_19_1
  doi: 10.1177/1357633X18795361
– ident: e_1_2_9_23_1
  doi: 10.1258/jtt.2012.120612
– ident: e_1_2_9_29_1
  doi: 10.1177/1357633X19885750
– ident: e_1_2_9_15_1
  doi: 10.1016/j.jsat.2016.12.014
– ident: e_1_2_9_2_1
– ident: e_1_2_9_17_1
  doi: 10.1016/j.drugpo.2018.06.019
– ident: e_1_2_9_13_1
  doi: 10.1016/s0027-9684(15)30161-9
– ident: e_1_2_9_18_1
– ident: e_1_2_9_24_1
  doi: 10.1155/2014/195097
– ident: e_1_2_9_27_1
  doi: 10.1111/jvh.13017
– ident: e_1_2_9_25_1
  doi: 10.5604/01.3001.0010.5277
– ident: e_1_2_9_26_1
  doi: 10.17235/reed.2019.6152/2018
– ident: e_1_2_9_28_1
  doi: 10.1177/1357633X18806651
SSID ssj0013251
Score 2.4518132
Snippet Hepatitis C virus (HCV) causes significant mortality worldwide. HCV is highly curable but access to care is limited for many patients. The Grady Liver Clinic...
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 176
SubjectTerms chronic disease
COVID-19
Health care access
Hepatitis C
Pandemics
Patients
Primary care
Telemedicine
urban population
vulnerable populations
Title A contactless cure: Leveraging telehealth to improve hepatitis C treatment at a safety‐net hospital
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjvh.13913
https://www.ncbi.nlm.nih.gov/pubmed/38369695
https://www.proquest.com/docview/2957142783
https://search.proquest.com/docview/2928584247
Volume 31
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9VAEB5KoeKLl3qLVlnFB19yyGV3k61PpVoOxfogVvoghEnOLKcIOdLkFOqTP8Hf2F_S2d0ktIogQh4Cu2GzmZnsNzuz8wG8VpgUC2myOJdEsdSNibEkG1ulrUrqBmnhzjsffdTzY3l4ok424O14FibUh5g23Jxl-P-1M3Csu-tGfr6cMXzxjLVpXrh0vnefsmsRBBWcLZXFiUrkUFXIZ_GMT95ci_4AmDfxql9wDu7C1_FVQ57Jt9m6r2fNj9-qOP7nXO7BnQGIir2gOfdhg9pt2ArUlBfbcOtoCLo_ANoTLqEdG1arrhPN-ox2xQdiG_AMR6LnlSscpxT9Spz6XQoSS3K52v1pJ_bFlM0ukC_RoaX-4vLnr5Z6sRyISx7C8cH7z_vzeGBniJucHdsYFcvUSMwJtWRQU6ByUVrGFyS1I7DXqTWUGkJsFJIpS43suTP8SmlRW5s_gs121dITEEmOSSPTBJN8wc22NNppSUaWypQ9xghejXKqvociHNXkvJwvK__pItgZJVgNdthVmVFF6tlEIng5NbMFubAItrRauz5ZyTAsk0UEj4Pkp1HYf9dGGxXBGy-_vw9fHX6Z-5un_971GdzOGCOFRKAd2OzP1vScMU5fv_DKfAVervhI
link.rule.ids 314,780,784,1375,27924,27925,46294,46718
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VRTwuPMorUMAgDlyyysP2xohLVaiWstsDalEvKJrNjrUVUhY12UrlxE_gN_JLGNtJ1IKQEFIOkezIcWa--BvPeAbgpcJkvJAmi3NJFEtdmRgLsrFV2qpkXiEt3Hnn2YGeHMn9Y3W8AW_6szAhP8Sw4eaQ4f_XDuBuQ_oiys-WI-YvrmTtFYZ76gK63n7MLvgQVDC3VBYnKpFdXiEfx9M_enk1-oNiXmasfsnZuwWf-5cNkSZfRut2Pqq-_ZbH8X9ncxtudlxU7ATluQMbVG_B1VCd8nwLrs06v_tdoB3hYtqxYs1qGlGtT-m1mBLDwBc5Ei0vXuFEpWhX4sRvVJBYkgvXbk8asSuGgHaBfIkGLbXnP7__qKkVy652yT042nt3uDuJuwINcZWzbRujYrEaiTmhlsxrxqico5YpBkntatjr1BpKDSFWCskUhUY23pmBpbSYW5vfh816VdNDEEmOSSXTBJN8wc22MNopSkaWipSNxghe9IIqv4Y8HOVgv5wtS__pItjuRVh2UGzKzKhx6guKRPB8aGYQOc8I1rRauz5ZwUwsk-MIHgTRD6OwCa-NNiqCV16Afx--3P808TeP_r3rM7g-OZxNy-n7gw-P4UbGlCnEBW3DZnu6pidMedr5U6_ZvwDstfxp
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NatwwEB5CQkMv_Un_3KatWnroxYstS1orPYWkyzZNQilNyaFgtPaIDQVviL2B5NRH6DP2STKSbJO0FErBB4NkZHlmrG80o_kA3kiTjCuheZwJxFioUscmRxtbqaxMZqXByp13PjhU0yOxdyyPV-BdfxYm1IcYNtycZfj_tTPw08peN_Lz-Yjgi2OsXROKa1c4f_czvxZCkMHbkjxOZCK6skI-jad_9OZi9AfCvAlY_YozuQvf-ncNiSbfR8t2Niovfyvj-J-TuQd3OiTKtoPq3IcVrDfgVuCmvNiA9YMu6v4AcJu5jHZTkl41DSuXZ7jF9pGMwFMcsZaWrnCekrULduK3KZDN0SVrtycN22FDOjszdLHGWGwvfv34WWPL5h1zyUM4mrz_sjONO3qGuMzIs42NJKFqYTI0ShCqGRvpwrQEMFAox2CvUqsx1WhMKQ3qPFeGXHfCXylWM2uzR7BaL2p8AizJTFKKNDFJVlGzzbVyasLRYp6SyxjB615OxWmowlEM3sv5vPCfLoLNXoJFZ4hNwbUcp55OJIJXQzOZkIuLmBoXS9eH54TDuBhH8DhIfhiFHHillZYRvPXy-_vwxd7Xqb95-u9dX8L6p91Jsf_h8OMzuM0JL4WkoE1Ybc-W-JzwTjt74fX6CgEl-xg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+contactless+cure%3A+Leveraging+telehealth+to+improve+hepatitis+C+treatment+at+a+safety-net+hospital&rft.jtitle=Journal+of+viral+hepatitis&rft.au=Frye%2C+Krysta&rft.au=Davis%2C+Andrew&rft.au=Darby%2C+Rapheisha&rft.au=McDaniel%2C+Kathryn&rft.date=2024-04-01&rft.eissn=1365-2893&rft.volume=31&rft.issue=4&rft.spage=176&rft.epage=180&rft_id=info:doi/10.1111%2Fjvh.13913&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1352-0504&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1352-0504&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1352-0504&client=summon